Tectonic Therapeutic (TECX) grants options and RSUs to CBO

Rhea-AI Filing Summary

Schwabish Marc reported acquisition or exercise transactions in this Form 4 filing.

Tectonic Therapeutic, Inc. Chief Business Officer Marc Schwabish reported receiving new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted 17,750 employee stock options and 19,500 shares of common stock represented by restricted stock units.

The restricted stock units each correspond to one share of common stock and are scheduled to vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to his continued service. The stock options vest in 48 equal monthly installments beginning on April 4, 2026, also conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Schwabish Marc

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	17,750	$0.00	--
Grant/Award	Common Stock	19,500	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 17,750 shares (Direct); Common Stock — 45,314 shares (Direct)

Footnotes (1)

1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwabish Marc

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		19,500(1)	A	$0	45,314	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$27.41	03/04/2026		A		17,750		(2)	03/03/2036	Common Stock	17,750	$0	17,750	D

Explanation of Responses:

1. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tectonic Therapeutic (TECX) report for Marc Schwabish?

Marc Schwabish, Chief Business Officer of Tectonic Therapeutic, reported equity awards rather than open‑market trades. On March 4, 2026, he acquired 17,750 employee stock options and 19,500 restricted stock units, each RSU representing one share of common stock, subject to future vesting.

How many restricted stock units did Marc Schwabish receive at Tectonic Therapeutic (TECX)?

Marc Schwabish received 19,500 restricted stock units tied to Tectonic Therapeutic common stock. Each RSU represents a contingent right to one share. These units vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, assuming continued service.

What are the vesting terms for Marc Schwabish’s restricted stock units at TECX?

The restricted stock units vest over three years. They are scheduled to vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, and each vesting date requires Marc Schwabish to remain in service with Tectonic Therapeutic.

What stock option grant did Marc Schwabish receive from Tectonic Therapeutic (TECX)?

Marc Schwabish was granted 17,750 employee stock options described as a right to buy Tectonic Therapeutic common stock. These options vest in 48 equal monthly installments beginning on April 4, 2026, with each monthly vesting conditioned on his continued service to the company.

How many Tectonic Therapeutic common shares did Marc Schwabish hold after these awards?

Following the March 4, 2026 equity awards, Marc Schwabish reported beneficial ownership of 45,314 Tectonic Therapeutic common shares. This figure reflects his direct holdings after the grant of 19,500 restricted stock units, which represent contingent rights to receive common shares upon vesting.

Do Marc Schwabish’s TECX equity awards involve any immediate cash transactions?

The reported transactions show equity awards coded as grants or other acquisitions rather than open‑market purchases. Both the restricted stock units and the employee stock options were granted on March 4, 2026, with no purchase price indicated, and are subject to multi‑year vesting schedules.